<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37167353</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4571</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>Circulation research</Title><ISOAbbreviation>Circ Res</ISOAbbreviation></Journal><ArticleTitle>Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment.</ArticleTitle><Pagination><StartPage>1320</StartPage><EndPage>1337</EndPage><MedlinePgn>1320-1337</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCRESAHA.123.321883</ELocationID><Abstract><AbstractText>The current epidemic of corona virus disease (COVID-19) has resulted in an immense health burden that became the third leading cause of death and potentially contributed to a decline in life expectancy in the United States. The severe acute respiratory syndrome-related coronavirus-2 binds to the surface-bound peptidase angiotensin-converting enzyme 2 (ACE2, EC 3.4.17.23) leading to tissue infection and viral replication. ACE2 is an important enzymatic component of the renin-angiotensin system (RAS) expressed in the lung and other organs. The peptidase regulates the levels of the peptide hormones Ang II and Ang-(1-7), which have distinct and opposing actions to one another, as well as other cardiovascular peptides. A potential consequence of severe acute respiratory syndrome-related coronavirus-2 infection is reduced ACE2 activity by internalization of the viral-ACE2 complex and subsequent activation of the RAS (higher ratio of Ang II:Ang-[1-7]) that may exacerbate the acute inflammatory events in COVID-19 patients and possibly contribute to the effects of long COVID-19. Moreover, COVID-19 patients present with an array of autoantibodies to various components of the RAS including the peptide Ang II, the enzyme ACE2, and the AT<sub>1</sub> AT<sub>2</sub> and Mas receptors. Greater disease severity is also evident in male COVID-19 patients, which may reflect underlying sex differences in the regulation of the 2 distinct functional arms of the RAS. The current review provides a critical evaluation of the evidence for an activated RAS in COVID-19 subjects and whether this system contributes to the greater severity of severe acute respiratory syndrome-related coronavirus-2 infection in males as compared with females.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chappell</LastName><ForeName>Mark C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-5869-6037</Identifier><AffiliationInfo><Affiliation>Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL146818</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circ Res</MedlineTA><NlmUniqueID>0047103</NlmUniqueID><ISSNLinking>0009-7330</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012084" MajorTopicYN="Y">Renin-Angiotensin System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">androgen</Keyword><Keyword MajorTopicYN="N">angiotensin-converting enzyme 2</Keyword><Keyword MajorTopicYN="N">estrogen</Keyword><Keyword MajorTopicYN="N">peptidyl-dipeptidase A</Keyword><Keyword MajorTopicYN="N">renin-angiotensin system</Keyword></KeywordList><CoiStatement><b>Disclosures</b> None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37167353</ArticleId><ArticleId IdType="pmc">PMC10171311</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.123.321883</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sch&#xf6;ley J, Aburto JM, Kashnitsky I, Kniffka MS, Zhang L, Jaadla H, Dowd JB, Kashyap R. Life expectancy changes since COVID-19. Nat Hum Behav. 2022;6:1649&#x2013;1659. doi: 10.1038/s41562-022-01450-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9755047</ArticleId><ArticleId IdType="pubmed">36253520</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiels MS, Haque AT, Berrington de Gonz&#xe1;lez A, Freedman ND. Leading causes of death in the US during the COVID-19 pandemic, March 2020 to October 2021. JAMA Intern Med. 2022;182:883&#x2013;886. doi: 10.1001/jamainternmed.2022.2476</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9257676</ArticleId><ArticleId IdType="pubmed">35788262</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolf SH, Chapman DA, Lee JH. COVID-19 as the leading cause of death in the United States. JAMA. 2021;325:123&#x2013;124. doi: 10.1001/jama.2020.24865</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553021</ArticleId><ArticleId IdType="pubmed">33331845</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuehn BM. Lowest US life expectancy since 1996 linked to COVID-19. JAMA. 2022;328:1389&#x2013;1390. doi: 10.1001/jama.2022.15454</Citation><ArticleIdList><ArticleId IdType="pubmed">36219401</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwani M, Yassin A, Al-Zoubi RM, Aboumarzouk OM, Nettleship J, Kelly D, Al-Qudimat AR, Shabsigh R. Sex-based differences in severity and mortality in COVID-19. Rev Med Virol. 2021;31:e2223. doi: 10.1002/rmv.2223</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014761</ArticleId><ArticleId IdType="pubmed">33646622</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, Chen S, Pasea L, Lai AG, Katsoulis M, Denaxas S, Nafilyan V, Williams B, Wong WK, Bakhai A, et al. . Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. Eur J Prev Cardiol. 2021;28:1599&#x2013;1609. doi: 10.1093/eurjpc/zwaa155</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928969</ArticleId><ArticleId IdType="pubmed">33611594</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciarelli V, Nasi M, Bianco F, Seferovic J, Ivkovic V, Gallina S, Mattioli AV. Depression pandemic and cardiovascular risk in the COVID-19 era and long COVID syndrome: gender makes a difference. Trends Cardiovasc Med. 2022;32:12&#x2013;17. doi: 10.1016/j.tcm.2021.09.009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8490128</ArticleId><ArticleId IdType="pubmed">34619336</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CC, Hsu CK, Yen MY, Lee PI, Ko WC, Hsueh PR. Long COVID: an inevitable sequela of SARS-CoV-2 infection. J Microbiol Immunol Infect. 2023;56:1&#x2013;9. doi: 10.1016/j.jmii.2022.10.003</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9576029</ArticleId><ArticleId IdType="pubmed">36283919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Yu M, Tong S, Liu LY, Tang LV. Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. J Clin Virol. 2020;127:104392. doi: 10.1016/j.jcv.2020.104392</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187844</ArticleId><ArticleId IdType="pubmed">32361327</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengs S, Rossi A, Haberecker M, Mikail N, Meisel A, Haider A, Gr&#xe4;mer M, Portmann A, Todorov A, Sch&#xf6;nenberger C, et al. . Immunoreactivity of the SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in murine models of hormonal manipulation, ageing, and cardiac injury. Sci Rep. 2021;11:23993. doi: 10.1038/s41598-021-03181-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8671541</ArticleId><ArticleId IdType="pubmed">34907257</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126:1456&#x2013;1474. doi: 10.1161/CIRCRESAHA.120.317015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188049</ArticleId><ArticleId IdType="pubmed">32264791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. . SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318:H1084&#x2013;H1090. doi: 10.1152/ajpheart.00217.2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191628</ArticleId><ArticleId IdType="pubmed">32228252</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?. Am J Physiol Heart Circ Physiol. 2016;310:H137&#x2013;H152. doi: 10.1152/ajpheart.00618.2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4796631</ArticleId><ArticleId IdType="pubmed">26475588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the Angiotensin converting enzyme 2-Angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne). 2014;4:201. doi: 10.3389/fendo.2013.00201</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3886117</ArticleId><ArticleId IdType="pubmed">24409169</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Peng J, Wang T, Wen J, Chen S, Huang Y, Zhang Y. Counter-regulatory renin-angiotensin system in hypertension: review and update in the era of COVID-19 pandemic. Biochem Pharmacol. 2022;208:115370. doi: 10.1016/j.bcp.2022.115370</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9721294</ArticleId><ArticleId IdType="pubmed">36481346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza-Torres E, Oyarz&#xfa;n A, Mondaca-Ruff D, Azocar A, Castro PF, Jalil JE, Chiong M, Lavandero S, Ocaranza MP. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis. 2015;9:217&#x2013;237. doi: 10.1177/1753944715597623</Citation><ArticleIdList><ArticleId IdType="pubmed">26275770</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ. The ACE2/Angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on Angiotensin-(1-7). Physiol Rev. 2018;98:505&#x2013;553. doi: 10.1152/physrev.00023.2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7203574</ArticleId><ArticleId IdType="pubmed">29351514</ArticleId></ArticleIdList></Reference><Reference><Citation>Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116:960&#x2013;975. doi: 10.1161/CIRCRESAHA.116.303587</Citation><ArticleIdList><ArticleId IdType="pubmed">25767283</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, et al. . Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826. doi: 10.1016/S0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lott N, Gebhard CE, Bengs S, Haider A, Kuster GM, Regitz-Zagrosek V, Gebhard C. Sex hormones in SARS-CoV-2 susceptibility: key players or confounders?. Nat Rev Endocrinol. 2022;19:1&#x2013;15. doi: 10.1038/s41574-022-00780-6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9734735</ArticleId><ArticleId IdType="pubmed">36494595</ArticleId></ArticleIdList></Reference><Reference><Citation>Trigunaite A, Dimo J, J&#xf8;rgensen TN. Suppressive effects of androgens on the immune system. Cell Immunol. 2015;294:87&#x2013;94. doi: 10.1016/j.cellimm.2015.02.004</Citation><ArticleIdList><ArticleId IdType="pubmed">25708485</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Gheblawi M, Nikhanj A, Munan M, MacIntyre E, O&#x2019;Neil C, Poglitsch M, Colombo D, Del Nonno F, Kassiri Z, et al. . Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and renin-angiotensin peptides in SARS-CoV-2 mediated mortality and end-organ injuries. Hypertension. 2022;79:365&#x2013;378. doi: 10.1161/HYPERTENSIONAHA.121.18295</Citation><ArticleIdList><ArticleId IdType="pubmed">34844421</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeland U, Coluzzi F, Simmaco M, Mura C, Bourne PE, Heiland M, Preissner R, Preissner S. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020;18:369. doi: 10.1186/s12916-020-01851-z</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7685778</ArticleId><ArticleId IdType="pubmed">33234138</ArticleId></ArticleIdList></Reference><Reference><Citation>Giagulli VA, Guastamacchia E, Magrone T, Jirillo E, Lisco G, De Pergola G, Triggiani V. Worse progression of COVID-19 in men: is testosterone a key factor?. Andrology. 2021;9:53&#x2013;64. doi: 10.1111/andr.12836</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307026</ArticleId><ArticleId IdType="pubmed">32524732</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumish HS, Kim E, Selvaggi C, Cao T, Gupta A, Foulkes AS, Reilly MP. Biomarkers of cardiac injury, renal injury, and inflammation are strong mediators of sex-associated death in COVID-19. Front Cardiovasc Med. 2022;9:809997. doi: 10.3389/fcvm.2022.809997</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9081502</ArticleId><ArticleId IdType="pubmed">35548417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, De Vries GJ, Epperson CN, Govindan R, Klein SL, et al. . Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396:565&#x2013;582. doi: 10.1016/S0140-6736(20)31561-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7440877</ArticleId><ArticleId IdType="pubmed">32828189</ArticleId></ArticleIdList></Reference><Reference><Citation>Twitchell DK, Christensen MB, Hackett G, Morgentaler A, Saad F, Pastuszak AW. Examining male predominance of severe COVID-19 outcomes: a systematic review. Androg Clin Res Ther. 2022;3:41&#x2013;53. doi: 10.1089/andro.2022.0006</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9527649</ArticleId><ArticleId IdType="pubmed">36199281</ArticleId></ArticleIdList></Reference><Reference><Citation>Viveiros A, Rasmuson J, Vu J, Mulvagh SL, Yip CYY, Norris CM, Oudit GY. Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. Am J Physiol Heart Circ Physiol. 2021;320:H296&#x2013;H304. doi: 10.1152/ajpheart.00755.2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083171</ArticleId><ArticleId IdType="pubmed">33275517</ArticleId></ArticleIdList></Reference><Reference><Citation>Muus C, Luecken MD, Eraslan G, Sikkema L, Waghray A, Heimberg G, Kobayashi Y, Vaishnav ED, Subramanian A, Smillie C, et al. ; NHLBI LungMap Consortium. Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. Nat Med. 2021;27:546&#x2013;559. doi: 10.1038/s41591-020-01227-z</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9469728</ArticleId><ArticleId IdType="pubmed">33654293</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444&#x2013;1448. doi: 10.1126/science.abb2762</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A detailed overview of SARS-CoV-2 Omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. Viruses. 2023;15:167. doi: 10.3390/v15010167</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9866114</ArticleId><ArticleId IdType="pubmed">36680207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, Kam TT, Gu H, Sit KY, Hsin MKY, et al. . SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603:715&#x2013;720. doi: 10.1038/s41586-022-04479-6</Citation><ArticleIdList><ArticleId IdType="pubmed">35104836</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, Abdullahi A, Ferreira I, Goonawardane N, Saito A, Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S, et al. . Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706&#x2013;714. doi: 10.1038/s41586-022-04474-x</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hikmet F, M&#xe9;ar L, Edvinsson A, Micke P, Uhl&#xe9;n M, Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol. 2020;16:e9610. doi: 10.15252/msb.20209610</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383091</ArticleId><ArticleId IdType="pubmed">32715618</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9:45. doi: 10.1186/s40249-020-00662-x</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186534</ArticleId><ArticleId IdType="pubmed">32345362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang Y, Luo W, Huang L, Xiao J, Li F, Qin S, Song X, Wu Y, Zeng Q, et al. . A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells. Int J Med Sci. 2020;17:1522&#x2013;1531. doi: 10.7150/ijms.46695</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359402</ArticleId><ArticleId IdType="pubmed">32669955</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;202:756&#x2013;759. doi: 10.1164/rccm.202001-0179LE</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462411</ArticleId><ArticleId IdType="pubmed">32663409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, et al. ; HCA Lung Biological Network. Electronic address: lung-network@humancellatlas.org. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016&#x2013;1035.e19. doi: 10.1016/j.cell.2020.04.035</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>South AM, Shaltout HA, Nixon PA, Diz DI, Jensen ET, O&#x2019;Shea TM, Chappell MC, Washburn LK. Association of circulating uric acid and angiotensin-(1-7) in relation to higher blood pressure in adolescents and the influence of preterm birth. J Hum Hypertens. 2020;34:818&#x2013;825. doi: 10.1038/s41371-020-0335-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606311</ArticleId><ArticleId IdType="pubmed">32346123</ArticleId></ArticleIdList></Reference><Reference><Citation>South AM, Shaltout HA, Washburn LK, hendrick AS, Diz DI, Chappell MC. Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data. Clin Sci (Lond). 2019;133:55&#x2013;74. doi: 10.1042/CS20171550</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716381</ArticleId><ArticleId IdType="pubmed">30622158</ArticleId></ArticleIdList></Reference><Reference><Citation>South AM, Nixon PA, Chappell MC, Diz DI, Russell GB, Shaltout HA, O&#x2019;Shea TM, Washburn LK. Obesity is associated with higher blood pressure and higher levels of angiotensin II but lower angiotensin-(1-7) in adolescents born preterm. J Pediatr. 2019;205:55&#x2013;60.e1. doi: 10.1016/j.jpeds.2018.09.058</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561332</ArticleId><ArticleId IdType="pubmed">30404738</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrario CM, Martell N, Yunis C, Flack JM, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, et al. . Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am J Hypertens. 1998;11:137&#x2013;146. doi: 10.1016/s0895-7061(97)00400-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9524041</ArticleId></ArticleIdList></Reference><Reference><Citation>Luque M, Maritin P, Martell N, Fenandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996;14:799&#x2013;805. doi: 10.1097/00004872-199606000-00017</Citation><ArticleIdList><ArticleId IdType="pubmed">8793704</ArticleId></ArticleIdList></Reference><Reference><Citation>Steckelings UM, Widdop RE, Sturrock ED, Lubbe L, Hussain T, Kaschina E, Unger T, Hallberg A, Carey RM, Sumners C. The angiotensin AT(2) receptor: from a binding site to a novel therapeutic target. Pharmacol Rev. 2022;74:1051&#x2013;1135. doi: 10.1124/pharmrev.120.000281</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9553111</ArticleId><ArticleId IdType="pubmed">36180112</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383:45&#x2013;51. doi: 10.1042/BJ20040634</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1134042</ArticleId><ArticleId IdType="pubmed">15283675</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekassy Z, Lopatko Fagerstr&#xf6;m I, Bader M, Karpman D. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Nat Rev Immunol. 2022;22:411&#x2013;428. doi: 10.1038/s41577-021-00634-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579187</ArticleId><ArticleId IdType="pubmed">34759348</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, Prindle T, Fulton WB, Wang S, McCray PB, Jr, Chappell MC, Hackam DJ, Jia H. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol. 2018;314:L17&#x2013;L31. doi: 10.1152/ajplung.00498.2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866432</ArticleId><ArticleId IdType="pubmed">28935640</ArticleId></ArticleIdList></Reference><Reference><Citation>Triposkiadis F, Starling RC, Xanthopoulos A, Butler J, Boudoulas H. The counter regulatory axis of the lung renin-angiotensin system in severe COVID-19: pathophysiology and clinical implications. Heart Lung Circ. 2021;30:786&#x2013;794. doi: 10.1016/j.hlc.2020.11.008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7831862</ArticleId><ArticleId IdType="pubmed">33454213</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes GMM, Do Nascimento IJB, Marazzi-Diniz PH, Da Silveira IB, Itaborahy MF, Viana LE, Silva FA, Santana MF, Pinto RA, Dutra BG, et al. . The des-Arg9-bradykinin/B1R axis: hepatic damage in COVID-19. Front Physiol. 2022;13:1080837. doi: 10.3389/fphys.2022.1080837</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9806358</ArticleId><ArticleId IdType="pubmed">36601349</ArticleId></ArticleIdList></Reference><Reference><Citation>Files DC, Gibbs KW, Schaich CL, Collins SP, Gwathmey TM, Casey JD, Self WH, Chappell MC. A pilot study to assess the circulating renin-angiotensin system in COVID-19 acute respiratory failure. Am J Physiol Lung Cell Mol Physiol. 2021;321:L213&#x2013;L218. doi: 10.1152/ajplung.00129.2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270515</ArticleId><ArticleId IdType="pubmed">34009036</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins SP, Chappell MC, Files DC. The renin-angiotensin-aldosterone system in COVID-19-related and non-COVID-19-related acute respiratory distress syndrome: not so different after all?. Am J Respir Crit Care Med. 2021;204:1007&#x2013;1008. doi: 10.1164/rccm.202108-1904ED</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8663005</ArticleId><ArticleId IdType="pubmed">34473935</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerard L, Lecocq M, Bouzin C, Hoton D, Schmit G, Pereira JP, Montiel V, Plante-Bordeneuve T, Laterre PF, Pilette C. Increased angiotensin-converting enzyme 2 and loss of alveolar type II cells in COVID-19-related acute respiratory distress syndrome. Am J Respir Crit Care Med. 2021;204:1024&#x2013;1034. doi: 10.1164/rccm.202012-4461OC</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8663012</ArticleId><ArticleId IdType="pubmed">34449302</ArticleId></ArticleIdList></Reference><Reference><Citation>Reindl-Schwaighofer R, H&#xf6;dlmoser S, Domenig O, Krenn K, Eskandary F, Krenn S, Sch&#xf6;rgenhofer C, Rumpf B, Karolyi M, Traugott MT, et al. . The systemic renin-angiotensin system in COVID-19. Sci Rep. 2022;12:20117. doi: 10.1038/s41598-022-24628-1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9684482</ArticleId><ArticleId IdType="pubmed">36418458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundstr&#xf6;m A, Ziegler L, Havervall S, Rudberg AS, von Meijenfeldt F, Lisman T, Mackman N, Sand&#xe9;n P, Th&#xe5;lin C. Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers. J Med Virol. 2021;93:5908&#x2013;5916. doi: 10.1002/jmv.27144</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426677</ArticleId><ArticleId IdType="pubmed">34138483</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SK, Juno JA, Lee WS, Wragg KM, Hogarth PM, Kent SJ, Burrell LM. Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. Eur Respir J. 2021;57:2003730. doi: 10.1183/13993003.03730-2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7830336</ArticleId><ArticleId IdType="pubmed">33479113</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieder M, Wirth L, Pollmeier L, Jeserich M, Goller I, Baldus N, Schmid B, Busch HJ, Hofmann M, Kern W, et al. . Serum ACE2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19. Am J Hypertens. 2021;34:278&#x2013;281. doi: 10.1093/ajh/hpaa169</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665331</ArticleId><ArticleId IdType="pubmed">33043967</ArticleId></ArticleIdList></Reference><Reference><Citation>Valle Martins AL, da Silva FA, Bolais-Ramos L, de Oliveira GC, Ribeiro RC, Pereira DAA, Annoni F, Diniz MML, Silva TGF, Zivianni B, et al. . Increased circulating levels of angiotensin-(1-7) in severely ill COVID-19 patients. ERJ Open Res. 2021;7:00114-2021. doi: 10.1183/23120541.00114-2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8326714</ArticleId><ArticleId IdType="pubmed">34350288</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lier D, Kox M, Santos K, van der Hoeven H, Pillay J, Pickkers P. Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients. ERJ Open Res. 2021;7:00848&#x2013;02020. doi: 10.1183/23120541.00848-2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848790</ArticleId><ArticleId IdType="pubmed">33738305</ArticleId></ArticleIdList></Reference><Reference><Citation>Pucci F, Annoni F, Santos RAS, Taccone FS, Rooman M. Quantifying renin-angiotensin-system alterations in COVID-19. Cells. 2021;10:2755. doi: 10.3390/cells1010275</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8535134</ArticleId><ArticleId IdType="pubmed">34685735</ArticleId></ArticleIdList></Reference><Reference><Citation>Miura Y, Ohkubo H, Nakano A, Bourke JE, Kanazawa S. Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung. Front Immunol. 2022;13:1028613. doi: 10.3389/fimmu.2022.1028613</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9673245</ArticleId><ArticleId IdType="pubmed">36405683</ArticleId></ArticleIdList></Reference><Reference><Citation>Tojo K, Yamamoto N, Tamada N, Mihara T, Abe M, Nishii M, Takeuchi I, Goto T. Early alveolar epithelial cell necrosis is a potential driver of COVID-19-induced acute respiratory distress syndrome. iScience. 2023;26:105748. doi: 10.1016/j.isci.2022.105748</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9722615</ArticleId><ArticleId IdType="pubmed">36507222</ArticleId></ArticleIdList></Reference><Reference><Citation>Klouda T, Hao Y, Kim H, Kim J, Olejnik J, Hume AJ, Ayyappan S, Hong X, Melero-Martin J, Fang Y, et al. . Interferon-alpha or -beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2. Angiogenesis. 2022;25:225&#x2013;240. doi: 10.1007/s10456-021-09823-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554520</ArticleId><ArticleId IdType="pubmed">34714440</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman DE, Mehta A, Taylor Thompson B, Charland NC, Gonye ALK, Gushterova I, Kays KR, Khanna HK, LaSalle TJ, Lavin-Parsons KM. Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19. Am J Respir Crit Care Med. 2022;205:507&#x2013;519. doi: 10.1164/rccm.202106-1514OC</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906476</ArticleId><ArticleId IdType="pubmed">34878969</ArticleId></ArticleIdList></Reference><Reference><Citation>Amezcua-Guerra LM, Del Valle L, Gonz&#xe1;lez-Pacheco H, Springall R, M&#xe1;rquez-Velasco R, Mass&#xf3; F, Brianza-Padilla M, Manzur-Sandoval D, Gonz&#xe1;lez-Flores J, Garc&#xed;a-&#xc1;vila C, et al. . The prognostic importance of the angiotensin II/angiotensin-(1-7) ratio in patients with SARS-CoV-2 infection. Ther Adv Respir Dis. 2022;16:17534666221122544. doi: 10.1177/17534666221122544</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9465579</ArticleId><ArticleId IdType="pubmed">36082632</ArticleId></ArticleIdList></Reference><Reference><Citation>Camargo RL, Bombassaro B, Monfort-Pires M, Mansour E, Palma AC, Ribeiro LC, Ulaf RG, Bernardes AF, Nunes TA, Agrela MV, et al. . Plasma Angiotensin II is increased in critical Coronavirus Disease 2019. Front Cardiovasc Med. 2022;9:847809. doi: 10.3389/fcvm.2022.847809</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9263116</ArticleId><ArticleId IdType="pubmed">35811697</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, et al. . Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364&#x2013;374. doi: 10.1007/s11427-020-1643-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088566</ArticleId><ArticleId IdType="pubmed">32048163</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniell H, Nair SK, Shi Y, Wang P, Montone KT, Shaw PA, Choi GH, Ghani D, Weaver J, Rader DJ, et al. . Decrease in Angiotensin-Converting Enzyme activity but not concentration in plasma/lungs in COVID-19 patients offers clues for diagnosis/treatment. Mol Ther Methods Clin Dev. 2022;26:266&#x2013;278. doi: 10.1016/j.omtm.2022.07.003</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258412</ArticleId><ArticleId IdType="pubmed">35818571</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman IO, Melenotte C, Brouqui P, Million M, Lagier JC, Parola P, Stein A, La Scola B, Meddeb L, Mege JL, et al. . Expression of ACE2, soluble ACE2, angiotensin I, angiotensin II and angiotensin-(1-7) is modulated in COVID-19 patients. Front Immunol. 2021;12:625732. doi: 10.3389/fimmu.2021.625732</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236950</ArticleId><ArticleId IdType="pubmed">34194422</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell MC, Pirro NT, South AM, Gwathmey TM. Concerns on the specificity of commercial ELISAs for the measurement of angiotensin-(1-7) and angiotensin II in human plasma. Hypertension. 2021;77:e29&#x2013;e31. doi: 10.1161/HYPERTENSIONAHA.120.16724</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7878344</ArticleId><ArticleId IdType="pubmed">33399002</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;ebek-Szatan&#xb4;ska A, Papierska L, Glinicki P, Zgliczyn&#xb4;ski W. Poor performance of Angiotensin II Enzyme-Linked Immuno-Sorbent assays in mostly hypertensive cohort routinely screened for primary aldosteronism. Diagnostics (Basel). 2022;12:1124. doi: 10.3390/diagnostics12051124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9139787</ArticleId><ArticleId IdType="pubmed">35626280</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Geurts F, Hassler L, Batlle D, Mirabito Colafella KM, Denton KM, Zhuo JL, Li XC, Ramkumar N, Koizumi M, et al. . Kidney angiotensin in cardiovascular disease: formation and drug targeting. Pharmacol Rev. 2022;74:462&#x2013;505. doi: 10.1124/pharmrev.120.000236</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9553117</ArticleId><ArticleId IdType="pubmed">35710133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew RA, Warner FJ, Hanchapola I, Yarski MA, Ramchand J, Burrell LM, Smith AI. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol. 2008;93:685&#x2013;693. doi: 10.1113/expphysiol.2007.040352</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197901</ArticleId><ArticleId IdType="pubmed">18223027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman EJ, Emmer BT. ACE2 protein expression within isogenic cell lines is heterogeneous and associated with distinct transcriptomes. Sci Rep. 2021;11:15900. doi: 10.1038/s41598-021-95308-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342525</ArticleId><ArticleId IdType="pubmed">34354120</ArticleId></ArticleIdList></Reference><Reference><Citation>Blume C, Jackson CL, Spalluto CM, Legebeke J, Nazlamova L, Conforti F, Perotin JM, Frank M, Butler J, Crispin M, et al. . A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. Nat Genet. 2021;53:205&#x2013;214. doi: 10.1038/s41588-020-00759-x</Citation><ArticleIdList><ArticleId IdType="pubmed">33432184</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams TL, Strachan G, Macrae RGC, Kuc RE, Nyimanu D, Paterson AL, Sinha S, Maguire JJ, Davenport AP. Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites. Sci Rep. 2021;11:24336. doi: 10.1038/s41598-021-03731-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8692523</ArticleId><ArticleId IdType="pubmed">34934117</ArticleId></ArticleIdList></Reference><Reference><Citation>Puskarich MA, Ingraham NE, Merck LH, Driver BE, Wacker DA, Black LP, Jones AE, Fletcher CV, South AM, Murray TA, et al. ; Angiotensin Receptor Blocker Based Lung Protective Strategies for Inpatients With COVID-19 (ALPS-IP) Investigators. Efficacy of losartan in hospitalized patients with COVID-19-induced lung injury: a randomized clinical trial. JAMA Netw Open. 2022;5:e222735. doi: 10.1001/jamanetworkopen.2022.2735</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8928006</ArticleId><ArticleId IdType="pubmed">35294537</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Chen Z, Ni L, Chen L, Zhou C, Gao C, Wu X, Hua L, Huang X, Cui X, et al. . Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the inflammatory response and viral clearance in COVID-19 patients. Front Cardiovasc Med. 2021;8:710946. doi: 10.3389/fcvm.2021.710946</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8416906</ArticleId><ArticleId IdType="pubmed">34490373</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MMY, Docherty KF, Sattar N, Mehta N, Kalra A, Nowacki AS, Solomon SD, Vaduganathan M, Petrie MC, Jhund PS, et al. . Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022;8:165&#x2013;178. doi: 10.1093/ehjcvp/pvaa138</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799280</ArticleId><ArticleId IdType="pubmed">33337478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocheleau GLY, Lee T, Mohammed Y, Goodlett D, Burns K, Cheng MP, Tran K, Sweet D, Marshall J, Slutsky AS, et al. ; for ARBs CORONA I Investigators. Renin-angiotensin system pathway therapeutics associated with improved outcomes in males hospitalized with COVID-19. Crit Care Med. 2022;50:1306&#x2013;1317. doi: 10.1097/CCM.0000000000005589</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9380153</ArticleId><ArticleId IdType="pubmed">35607951</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornling G, Batta R, Porter JC, Williams B, Bengtsson T, Parmar K, Kashiva R, Hallberg A, Cohrt AK, Westergaard K, et al. . Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial. EClinicalMedicine. 2021;41:101152. doi: 10.1016/j.eclinm.2021.101152</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542174</ArticleId><ArticleId IdType="pubmed">34723163</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce E, Shenoy V, Rathinasabapathy A, Espejo A, Horowitz A, Oswalt A, Francis J, Nair A, Unger T, Raizada MK, et al. . Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. Br J Pharmacol. 2015;172:2219&#x2013;2231. doi: 10.1111/bph.13044</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4403089</ArticleId><ArticleId IdType="pubmed">25522140</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicore provides an update on the ATTRACT-3 COVID-19 trial. Vicore Pharma Holding AB.
2022. https://vicorepharma.com/cision-feed/vicore-provides-an-update-on-the-attract-3-covid-19-trial/</Citation></Reference><Reference><Citation>Serpa Neto A, Landoni G, Osetermann M, Lulertgul N, Forni L, Alavarz-Belon L, Trapnani T, Alliegro PV, Zacharowski K, Wiedenbeck C, et al. . Angiotensin II infusion in COVID-19: an international, multicenter, registry-based study. J Med Virol. 2022;94:2079&#x2013;2088. doi: 10.1002/jmv.27592</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015246</ArticleId><ArticleId IdType="pubmed">35029318</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse LW, Chow JH, McCurdy MT, Khanna AK. COVID-19 and the RAAS-a potential role for angiotensin II?. Crit Care. 2020;24:136. doi: 10.1186/s13054-020-02862-1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7137402</ArticleId><ArticleId IdType="pubmed">32264922</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, Hastbacka J, Khanna AK, Aberston TE, Tumlin J, et al. . Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med. 2020;202:1253&#x2013;1261. doi: 10.1164/rccm.201911-2172OC</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7605187</ArticleId><ArticleId IdType="pubmed">32609011</ArticleId></ArticleIdList></Reference><Reference><Citation>Abadir PM, Jain A, Powell LJ, Xue QL, Tian J, Hamilton RG, Bennett DA, Finucane T, Walston JD, Fedarko NS. Discovery and validation of agonistic angiotensin receptor autoantibodies as biomarkers of adverse outcomes. Circulation. 2017;135:449&#x2013;459. doi: 10.1161/CIRCULATIONAHA.116.022385</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5285272</ArticleId><ArticleId IdType="pubmed">27903588</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer J, Liu R, Lu Y, Scott J, Wallace K, Wallukat G, Moseley J, Herse F, Dechend R, Martin JN, Jr, et al. . Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy. Hypertension. 2013;62:886&#x2013;892. doi: 10.1161/HYPERTENSIONAHA.113.01648</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845356</ArticleId><ArticleId IdType="pubmed">24041954</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Marques O, Halpert G, Schimke LF, Ostrinski Y, Vojdani A, Baiocchi GC, Freire PP, Filgueiras IS, Zyskind I, Lattin MT, et al. . Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat Commun. 2022;13:1220. doi: 10.1038/s41467-022-28905-5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8907309</ArticleId><ArticleId IdType="pubmed">35264564</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell MC. Angiotensin-converting enzyme 2 autoantibodies: further evidence for a role of the renin-angiotensin system in inflammation. Arthritis Res Ther. 2010;12:128. doi: 10.1186/ar3052</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911909</ArticleId><ArticleId IdType="pubmed">20602809</ArticleId></ArticleIdList></Reference><Reference><Citation>Civieri G, Iop L, Tona F. Antibodies against angiotensin II type 1 and endothelin 1 type A receptors in cardiovascular pathologies. Int J Mol Sci. 2022;23:927. doi: 10.3390/ijms23020927</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8778295</ArticleId><ArticleId IdType="pubmed">35055116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao ZW, Zhang HZ, Liu C, Dong K. Autoantibodies in COVID-19: frequency and function. Autoimmun Rev. 2021;20:102754. doi: 10.1016/j.autrev.2021.102754</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7813482</ArticleId><ArticleId IdType="pubmed">33476817</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejia-Vilet JM, L&#xf3;pez-Hern&#xe1;ndez YJ, Santander-V&#xe9;lez JI, Trujeque-Matos M, Cruz C, Carranza de la Torre CA, Espinosa-Cruz V, Espinosa-Gonz&#xe1;lez R, Uribe-Uribe NO, Morales-Buenrostro LE. Angiotensin II receptor agonist antibodies are associated with microvascular damage in lupus nephritis. Lupus. 2020;29:371&#x2013;378. doi: 10.1177/0961203320904787</Citation><ArticleIdList><ArticleId IdType="pubmed">32041505</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemekasten G, Petersen F, Heidecke H. What makes antibodies against G protein-coupled receptors so special? A novel concept to understand chronic diseases. Front Immunol. 2020;11:564526. doi: 10.3389/fimmu.2020.564526</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7770155</ArticleId><ArticleId IdType="pubmed">33384684</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Perez AI, Labandeira CM, Pedrosa MA, Valenzuela R, Suarez-Quintanilla JA, Cortes-Ayaso M, May&#xe1;n-Conesa P, Labandeira-Garcia JL. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun. 2021;122:102683. doi: 10.1016/j.jaut.2021.102683</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193025</ArticleId><ArticleId IdType="pubmed">34144328</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, Sep&#xfa;lveda N, Mathias da Fonseca DL, Baiocchi GC, Marques AHC, et al. . Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front Immunol. 2022;13:981532. doi: 10.3389/fimmu.2022.981532</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552223</ArticleId><ArticleId IdType="pubmed">36238301</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Haga S, Ishizaka Y, Mimori A. Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases. Arthritis Res Ther. 2010;12:R85. doi: 10.1186/ar3012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911869</ArticleId><ArticleId IdType="pubmed">20470389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen. 2011;16:878&#x2013;885. doi: 10.1177/1087057111413919</Citation><ArticleIdList><ArticleId IdType="pubmed">21859683</ArticleId></ArticleIdList></Reference><Reference><Citation>Casciola-Rosen L, Thiemann DR, Andrade F, Trejo-Zambrano MI, Leonard EK, Spangler JB, Skinner NE, Bailey J, Yegnasubramanian S, Wang R, et al. . IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight. 2022;7:e158362. doi: 10.1172/jci.insight.158362</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9090251</ArticleId><ArticleId IdType="pubmed">35349483</ArticleId></ArticleIdList></Reference><Reference><Citation>Briquez PS, Rouhani SJ, Yu J, Pyzer AR, Trujillo J, Dugan HL, Stamper CT, Changrob S, Sperling AI, Wilson PC, et al. . Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci Adv. 2022;8:eabn3777. doi: 10.1126/sciadv.abn3777</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9544317</ArticleId><ArticleId IdType="pubmed">36206332</ArticleId></ArticleIdList></Reference><Reference><Citation>Miedema J, Schreurs M, van der Sar-van der Brugge S, Paats M, Baart S, Bakker M, Hoek R, Dik WA, Endeman H, Van Der Velden V, et al. . Antibodies against angiotensin II receptor type 1 and endothelin A receptor are associated with an unfavorable COVID19 disease course. Front Immunol. 2021;12:684142. doi: 10.3389/fimmu.2021.684142</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155664</ArticleId><ArticleId IdType="pubmed">34054876</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y, Kellems RE. Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ Res. 2013;113:78&#x2013;87. doi: 10.1161/CIRCRESAHA.113.300752</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4131731</ArticleId><ArticleId IdType="pubmed">23788505</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue X, Yin J, Wang X, Heidecke H, Hackel AM, Dong X, Kasper B, Wen L, Zhang L, Schulze-Forster K, et al. . Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching. Ann Rheum Dis. 2022;81:1281&#x2013;1289. doi: 10.1136/annrheumdis-2021-222088</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9380513</ArticleId><ArticleId IdType="pubmed">35595388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian J, Lei J, Yin X, Wang P, Wu Y, Yang X, Wang L, Zhang S, Liu H, Fu MLX. Limited AT1 receptor internalization is a novel mechanism underlying sustained vasoconstriction induced by AT1 receptor autoantibody from preeclampsia. J Am Heart Assoc. 2019;8:e011179. doi: 10.1161/JAHA.118.011179</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6475063</ArticleId><ArticleId IdType="pubmed">30845870</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder M, Schaumburg B, Mueller Z, Parplys A, Jarczak D, Roedl K, Nierhaus A, de Heer G, Grensemann J, Schneider B, et al. . High estradiol and low testosterone levels are associated with critical illness in male but not in female COVID-19 patients: a retrospective cohort study. Emerg Microbes Infect. 2021;10:1807&#x2013;1818. doi: 10.1080/22221751.2021.1969869</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451658</ArticleId><ArticleId IdType="pubmed">34402750</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendergrass KD, Pirro NT, Westwood BM, Ferrario CM, Brosnihan KB, Chappell MC. Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats. Am J Physiol Heart Circ Physiol. 2008;295:H10&#x2013;H20. doi: 10.1152/ajpheart.01277.2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2494740</ArticleId><ArticleId IdType="pubmed">18456730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell MC, Gallagher PE, Averill DB, Ferrario CM, Brosnihan KB. Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat. Hypertension. 2003;42:781&#x2013;786. doi: 10.1161/01.HYP.0000085210.66399.A3</Citation><ArticleIdList><ArticleId IdType="pubmed">12874087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology. 2009;150:3753&#x2013;3758. doi: 10.1210/en.2008-1664</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717873</ArticleId><ArticleId IdType="pubmed">19372194</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosnihan KB, Li P, Ganten D, Ferrario CM. Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS. Am J Physiol. 1997;273:R1908&#x2013;R1915. doi: 10.1152/ajpregu.1997.273.6.R1908</Citation><ArticleIdList><ArticleId IdType="pubmed">9435644</ArticleId></ArticleIdList></Reference><Reference><Citation>Reckelhoff JF, Romero DG, Yanes Cardozo LL. Sex, oxidative stress, and hypertension: insights from animal models. Physiology (Bethesda). 2019;34:178&#x2013;188. doi: 10.1152/physiol.00035.2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6734067</ArticleId><ArticleId IdType="pubmed">30968750</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman MA, Harris RA, Sullivan JC. Female spontaneously hypertensive rats are more dependent on ANG (1-7) to mediate effects of low-dose AT1 receptor blockade than males. Am J Physiol Renal Physiol. 2014;306:F1136&#x2013;F1142. doi: 10.1152/ajprenal.00677.2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4024730</ArticleId><ArticleId IdType="pubmed">24647710</ArticleId></ArticleIdList></Reference><Reference><Citation>Visniauskas B, Kilanowski-Doroh I, Ogola BO, McNally AB, Horton AC, Imulinde Sugi A, Lindsey SH. Estrogen-mediated mechanisms in hypertension and other cardiovascular diseases. J Hum Hypertens. 2022; doi: 10.1038/s41371-022-00771-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10919324</ArticleId><ArticleId IdType="pubmed">36319856</ArticleId></ArticleIdList></Reference><Reference><Citation>Samposon AK, Moriz KM, Jones ES, Flower RL, Widdop RE, Denton KM. Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension. 2008;52:666&#x2013;671. doi: 10.1161/HYPERTENSIONAHA.108.114058</Citation><ArticleIdList><ArticleId IdType="pubmed">18711010</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow BS, Kocan M, Bosnyak S, Sarwar M, Wigg B, Jones ES, Widdop RE, Summers RJ, Bathgate RA, Hewitson TD, et al. . Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. Kidney Int. 2014;86:75&#x2013;85. doi: 10.1038/ki.2013.518</Citation><ArticleIdList><ArticleId IdType="pubmed">24429402</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima N, Patel SN, Hussain T. Angiotensin II type 2 receptor: a target for protection against hypertension, metabolic dysfunction, and organ remodeling. Hypertension. 2021;77:1845&#x2013;1856. doi: 10.1161/HYPERTENSIONAHA.120.11941</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8115429</ArticleId><ArticleId IdType="pubmed">33840201</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan JC, Rodriguez-Miguelez P, Zimmerman MA, Harris RA. Differences in angiotensin (1-7) between men and women. Am J Physiol Heart Circ Physiol. 2015;308:H1171&#x2013;H1176. doi: 10.1152/ajpheart.00897.2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551129</ArticleId><ArticleId IdType="pubmed">25659489</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Engel A, Morcillo L, Aranda FJ, Ruiz M, Gaitan MJ, Mayor-Olea A, Aranda P, Ferrario CM. Influence of gender and genetic variability on plasma angiotensin peptides. J Renin Angiotensin Aldosterone Syst. 2006;7:92&#x2013;97. doi: 10.3317/jraas.2006.015</Citation><ArticleIdList><ArticleId IdType="pubmed">17083063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One. 2018;13:e0198144. doi: 10.1371/journal.pone.0198144</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5999069</ArticleId><ArticleId IdType="pubmed">29897923</ArticleId></ArticleIdList></Reference><Reference><Citation>Narula S, Yusuf S, Chong M, Ramasundarahettige C, Rangarajan S, Bangdiwala SI, van Eikels M, Leineweber K, Wu A, Pigeyre M, et al. . Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. Lancet. 2020;396:968&#x2013;976. doi: 10.1016/S0140-6736(20)31964-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7529405</ArticleId><ArticleId IdType="pubmed">33010842</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res. 2006;98:1123&#x2013;1133. doi: 10.1161/01.RES.0000223145.74217.e7</Citation><ArticleIdList><ArticleId IdType="pubmed">16690893</ArticleId></ArticleIdList></Reference><Reference><Citation>Serfozo P, Wysocki J, Gulua G, Schulze A, Ye M, Liu P, Jin J, Bader M, My&#xf6;h&#xe4;nen T, Garc&#xed;a-Horsman JA, et al. . Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension. 2020;75:173&#x2013;182. doi: 10.1161/HYPERTENSIONAHA.119.14071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286421</ArticleId><ArticleId IdType="pubmed">31786979</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel DF, Snelgrove RJ. The multifaceted roles of the matrikine Pro-Gly-Pro in pulmonary health and disease. Eur Respir Rev. 2018;27:180017. doi: 10.1183/16000617.0017-2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9488800</ArticleId><ArticleId IdType="pubmed">29950303</ArticleId></ArticleIdList></Reference><Reference><Citation>Self WH, Shotwell MS, Gibbs KW, DeWit M, Files DC, Harkins M, Hudock K, Merkc L, Moskowitz A, Apocada KD, et al. . Effect of renin-angiotensin system modulation with synthetic angiotensin (1-7) [TXA-127] and an AT1R biased ligand [TRV-027] a mong adults with COVID-19-induced acute lung injury: randomized clinical trials. JAMA. 2023;29:1170-1182. doi: 10.1001/jama.2023.3546</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10091180</ArticleId><ArticleId IdType="pubmed">37039791</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell MC, Alzayadneh EM. Angiotensin-(1-7) and the regulation of anti-fibrotic signaling pathways. J Cell Signal. 2017;2:134. doi: 10.4172/2576-1471.1000134</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501273</ArticleId><ArticleId IdType="pubmed">28691117</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta D, Kumar A, Mandloi A, Shenoy V. Renin angiotensin aldosterone system in pulmonary fibrosis: pathogenesis to therapeutic possibilities. Pharmacol Res. 2021;174:105924. doi: 10.1016/j.phrs.2021.105924</Citation><ArticleIdList><ArticleId IdType="pubmed">34607005</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee for the REMAP-CAP Investigators. Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support&#x2013;free days in patients hospitalized with COVID-19 a randomized clinical trial. JAMA. 2023;329:1183&#x2013;1196. doi: 10.1001/jama.2023.4480</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10326520</ArticleId><ArticleId IdType="pubmed">37039790</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Q, Rasool RU, Russell RM, Natesan R, Asangani IA. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. iScience. 2021;24:102254. doi: 10.1016/j.isci.2021.102254</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919514</ArticleId><ArticleId IdType="pubmed">33681723</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi A, Nowroozi A, Alilou S, Amini E. Effects of androgen deprivation therapy on COVID-19 in patients with prostate cancer: a systematic review and meta-analysis. Urol J. 2021;18:577&#x2013;584. doi: 10.22037/uj.v18i.6691</Citation><ArticleIdList><ArticleId IdType="pubmed">34302737</ArticleId></ArticleIdList></Reference><Reference><Citation>Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, et al. . Long-term efficacy and safety of enzalutamide monotherapy in hormone-na&#xef;ve prostate cancer: 1- and 2-year open-label follow-up results. Eur Urol. 2015;68:787&#x2013;794. doi: 10.1016/j.eururo.2015.01.027</Citation><ArticleIdList><ArticleId IdType="pubmed">25687533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wel&#xe9;n K, Rosendal E, Gissl&#xe9;n M, Lenman A, Freyhult E, Fonseca-Rodr&#xed;guez O, Bremell D, Stranne J, Balkhed A, Niward K, et al. . A phase 2 trial of the effect of antiandrogen therapy on COVID-19 outcome: no evidence of benefit, supported by epidemiology and in vitro data. Eur Urol. 2022;81:285&#x2013;293. doi: 10.1016/j.eururo.2021.12.013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8673828</ArticleId><ArticleId IdType="pubmed">34980495</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickols NG, Mi Z, DeMatt E, Biswas K, Clise CE, Huggins JT, Maraka S, Ambrogini E, Mirsaeidi MS, Levin ER, et al. . Effect of androgen suppression on clinical outcomes in hospitalized men with COVID-19: the HITCH randomized clinical trial. JAMA Netw Open. 2022;5:e227852. doi: 10.1001/jamanetworkopen.2022.7852</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9020208</ArticleId><ArticleId IdType="pubmed">35438754</ArticleId></ArticleIdList></Reference><Reference><Citation>Infante M, Pieri M, Lupisella S, D&#x2019;Amore L, Bernardini S, Fabbri A, Iannetta M, Andreoni M, Morello M. Low testosterone levels and high estradiol to testosterone ratio are associated with hyperinflammatory state and mortality in hospitalized men with COVID-19. Eur Rev Med Pharmacol Sci. 2021;25:5889&#x2013;5903. doi: 10.26355/eurrev_202110_26865</Citation><ArticleIdList><ArticleId IdType="pubmed">34661247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanser L, Burkert FR, Thommes L, Egger A, Hoermann G, Kaser S, Pinggera GM, Anliker M, Griesmacher A, Weiss G, et al. . Testosterone deficiency is a risk factor for severe COVID-19. Front Endocrinol (Lausanne). 2021;12:694083. doi: 10.3389/fendo.2021.694083</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8253686</ArticleId><ArticleId IdType="pubmed">34226825</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Wong P, Ellingson MK, Lucas C, Klein J, Israelow B, Silva J, Oh JE, Mao T, Tokuyama M, et al. . Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes. Nature. 2020;588:315&#x2013;320. doi.org/10.1038/s41586-020-2700-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725931</ArticleId><ArticleId IdType="pubmed">32846427</ArticleId></ArticleIdList></Reference><Reference><Citation>Toscano-Guerra E, Mart&#xed;nez-Gallo M, Arrese-Mu&#xf1;oz I, Gin&#xe9; A, D&#xed;az-Troyano N, Gabriel-Medina P, Riveiro-Barciela M, Labrador-Horrillo M, Martinez-Valle F, Montalv&#xe1; AS, et al. . Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients. BMC Med. 2022;20:129. doi: 10.1186/s12916-022-02345-w</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8963401</ArticleId><ArticleId IdType="pubmed">35351135</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zeggeren IE, Boelen A, van de Beek D, Heijboer AC, Vlaar APJ, Brouwer MC; Amsterdam UMC COVID-19 Biobank. Sex steroid hormones are associated with mortality in COVID-19 patients: level of sex hormones in severe COVID-19. Medicine (Baltim). 2021;100:e27072. doi: 10.1097/MD.0000000000027072</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389969</ArticleId><ArticleId IdType="pubmed">34449505</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassin A, Sabsigh R, Al-Zoubi RM, Aboumarzouk OM, Alwani M, Nettleship J, Kelly D. Testosterone and Covid-19: an update. Rev Med Virol. 2022;33:e2395. doi: 10.1002/rmv.2395</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537909</ArticleId><ArticleId IdType="pubmed">36056748</ArticleId></ArticleIdList></Reference><Reference><Citation>Young MJ, Clyne CD, Chapman KE. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. J Endocrinol. 2020;247:R45&#x2013;R62. doi: 10.1530/JOE-20-0260</Citation><ArticleIdList><ArticleId IdType="pubmed">32966970</ArticleId></ArticleIdList></Reference><Reference><Citation>Afshari P, Zakerkish M, Abedi P, Beheshtinasab M, Maraghi E, Meghdadi H. Effect of COVID-19 infection on sex hormone levels in hospitalized patients: a prospective longitudinal study in Iran. Health Sci Rep. 2023;6:e1011. doi: 10.1002/hsr2.1011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9789677</ArticleId><ArticleId IdType="pubmed">36582631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhasin S, Lincoff AM, Basaria S, Bauer DC, Boden WE, Cunningham GR, Davey D, Dubcenco E, Fukumoto S, Garcia M, et al. ; TRAVERSE Study Investigators. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. Am Heart J. 2022;245:41&#x2013;50. doi: 10.1016/j.ahj.2021.11.016</Citation><ArticleIdList><ArticleId IdType="pubmed">34871580</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur H, Werstuck GH. The effect of testosterone on cardiovascular disease and cardiovascular risk factors in men: a review of clinical and preclinical data. CJC Open. 2021;3:1238&#x2013;1248. doi: 10.1016/j.cjco.2021.05.007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8636244</ArticleId><ArticleId IdType="pubmed">34888506</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallone JN, Oloyo AK. Cardiovascular and metabolic actions of the androgens: is testosterone a Janus-faced molecule?. Biochem Pharmacol. 2022;208:115347. doi: 10.1016/j.bcp.2022.115347</Citation><ArticleIdList><ArticleId IdType="pubmed">36395900</ArticleId></ArticleIdList></Reference><Reference><Citation>Traish AM, Haider A, Haider KS, Doros G, Saad F. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther. 2017;22:414&#x2013;433. doi: 10.1177/1074248417691136</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5555449</ArticleId><ArticleId IdType="pubmed">28421834</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HH, Tu SK, Chen HH, Hung CL, Kuo CW, Tsan YT, Chu WM, Lee MC, Liao CC. Testosterone level reduction increases the 10-year risk of cardiovascular diseases: a retrospective cohort study in a Taiwanese young male population. Front Cardiovasc Med. 2022;9:869251. doi: 10.3389/fcvm.2022.869251</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047944</ArticleId><ArticleId IdType="pubmed">35498035</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan C, Lu W, Li K, Ding Y, Wang J. ACE2 expression in kidney and testis may cause kidney and testis infection in COVID-19 patients. Front Med (Lausanne). 2020;7:563893. doi: 10.3389/fmed.2020.563893</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7838217</ArticleId><ArticleId IdType="pubmed">33521006</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Chen S, Huang B, Zhong JM, Su H, Chen YJ, Cao Q, Ma L, He J, Li XF, et al. . Pathological findings in the testes of COVID-19 patients: clinical implications. Eur Urol Focus. 2020;6:1124&#x2013;1129. doi: 10.1016/j.euf.2020.05.009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261470</ArticleId><ArticleId IdType="pubmed">32563676</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianzo M, Subir&#xe1;n N. Regulation of male fertility by the renin-angiotensin system. Int J Mol Sci. 2020;21:7943. doi: 10.3390/ijms21217943</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662798</ArticleId><ArticleId IdType="pubmed">33114706</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufau ML, Ulisse S, Khanum A, Buczko E, Kitamura M, Fabbri A, Namiki M. LH action in the Leydig cell: modulation by angiotensin II and corticotropin releasing hormone, and regulation of P450(17) alpha mRNA. J Steroid Biochem. 1989;34:205&#x2013;217. doi: 10.1016/0022-4731(89)90084-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2696845</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z, Zhong J, Jiang Y, Zhang J. Associations between COVID-19 infection and sex steroid hormones. Front Endocrinol (Lausanne). 2022;13:940675. doi: 10.3389/fendo.2022.940675</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9592769</ArticleId><ArticleId IdType="pubmed">36303865</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhindsa S, Zhang N, McPhaul MJ, Wu Z, Ghoshal AK, Erlich EC, Mani K, Randolph GJ, Edwards JR, Mudd PA, et al. . Association of circulating sex hormones with inflammation and disease severity in patients with COVID-19. JAMA Netw Open. 2021;4:e2111398. doi: 10.1001/jamanetworkopen.2021.11398</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8150664</ArticleId><ArticleId IdType="pubmed">34032853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubbels Bupp MR, Jorgensen TN. Androgen-induced immunosuppression. Front Immunol. 2018;9:794. doi: 10.3389/fimmu.2018.00794</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932344</ArticleId><ArticleId IdType="pubmed">29755457</ArticleId></ArticleIdList></Reference><Reference><Citation>Perusqu&#xed;a M. Androgens and non-genomic vascular responses in hypertension. Biochem Pharmacol. 2022;203:115200. doi: 10.1016/j.bcp.2022.115200</Citation><ArticleIdList><ArticleId IdType="pubmed">35926652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagen SH, Henseling F, Hennesen J, Savel H, Delahaye S, Richert L, Ziegler SM, Altfeld M. Heterogeneous escape from X chromosome inactivation results in sex differences in type I IFN responses at the single human pDC level. Cell Rep. 2020;33:108485. doi: 10.1016/j.celrep.2020.108485</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833293</ArticleId><ArticleId IdType="pubmed">33296655</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiering AE, de Vries TJ. Why females do better: the X chromosomal TLR7 gene-dose effect in COVID-19. Front Immunol. 2021;12:756262. doi: 10.3389/fimmu.2021.756262</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632002</ArticleId><ArticleId IdType="pubmed">34858409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bencze D, Fekete T, P&#xe1;zm&#xe1;ndi K. Correlation between type I interferon associated factors and COVID-19 severity. Int J Mol Sci. 2022;23:10968. doi: 10.3390/ijms231810968</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9506204</ArticleId><ArticleId IdType="pubmed">36142877</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis ML, Maselli A, Pagano MT, Pierdominici M, Ortona E. Immune response and autoimmune diseases: a matter of sex. Ital J Gender-Specific Med. 2019;5:11&#x2013;20. doi: 10.1723/3148.31294</Citation></Reference><Reference><Citation>Lau ES, McNeill JN, Paniagua SM, Liu EE, Wang JK, Bassett IV, Selvaggi CA, Lubitz SA, Foulkes AS, Ho JE. Sex differences in inflammatory markers in patients hospitalized with COVID-19 infection: insights from the MGH COVID-19 patient registry. PLoS One. 2021;16:e0250774. doi: 10.1371/journal.pone.0250774</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8081177</ArticleId><ArticleId IdType="pubmed">33909684</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Boon ACM, Michelson AP, Foraker RE, Zhan M, Payne PRO. Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19. Sci Rep. 2022;12:9462. doi: 10.1038/s41598-022-13585-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9175532</ArticleId><ArticleId IdType="pubmed">35676404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sund M, Fonseca-Rodr&#xed;guez O, Josefsson A, Welen K, Fors Connolly AM. Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort study. BMJ Open. 2022;12:e053032. doi: 10.1136/bmjopen-2021-053032</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8844968</ArticleId><ArticleId IdType="pubmed">35165090</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakal S, Ruiz-Bedoya CA, Zhou R, Creisher PS, Villano JS, Littlefield K, Ruelas Castillo J, Marinho P, Jedlicka AE, Ordonez AA, et al. ; Johns Hopkins COVID-19 Hamster Study Group. Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 Golden Syrian Hamster model. mBio. 2021;12:e0097421. doi: 10.1128/mBio.00974-21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406232</ArticleId><ArticleId IdType="pubmed">34253053</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa AJ, Lemes RMR, Bartolomeo CS, Nunes TA, Pereira GC, Oliveira RB, Gomes AL, Smaili SS, Maciel RMB, Newson L, et al. . Overexpression of estrogen receptor GPER1 and G1 treatment reduces SARS-CoV-2 infection in BEAS-2B bronchial cells. Mol Cell Endocrinol. 2022;558:111775. doi: 10.1016/j.mce.2022.111775</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9458763</ArticleId><ArticleId IdType="pubmed">36096380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22:57&#x2013;65. doi: 10.1038/s41577-021-00662-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8649989</ArticleId><ArticleId IdType="pubmed">34876702</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, de Oliveira MHS, Peligro PJ, Velasco JV, Macaranas I, Ver AT, Pangilinan FC, Pastrana A, Goldrich N, Kavteladze D, et al. . Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: a systematic review and meta-Analysis. J Clin Med. 2022;11:7314. doi: 10.3390/jcm11247314</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9787827</ArticleId><ArticleId IdType="pubmed">36555931</ArticleId></ArticleIdList></Reference><Reference><Citation>Szewczykowski C, Mardin C, Lucio M, Wallukat G, Hoffmanns J, Schr&#xf6;der T, Raith F, Rogge L, Heltmann F, Moritz M, et al. . Long COVID: association of functional autoantibodies against G-protein-coupled receptors with an impaired retinal microcirculation. Int J Mol Sci. 2022;23:7209. doi: 10.3390/ijms23137209</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9266742</ArticleId><ArticleId IdType="pubmed">35806214</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, F&#xfc;rst J, Schulze-Rothe S, Wallukat A, H&#xf6;nicke AS, M&#xfc;ller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619. doi: 10.1016/j.eclinm.2022.101619</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9366236</ArticleId><ArticleId IdType="pubmed">35971425</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth GA, Vaduganathan M, Mensah GA. Impact of the COVID-19 pandemic on cardiovascular health in 2020: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80:631&#x2013;640. doi: 10.1016/j.jacc.2022.06.008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9341480</ArticleId><ArticleId IdType="pubmed">35926937</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi ZA, Dalal R, Sadhu S, Binayke A, Dandotiya J, Kumar Y, Shrivastava T, Gupta SK, Aggarwal S, Tripathy MR, et al. . Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection. Elife. 2022;11:e73522. doi: 10.7554/eLife.73522</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8794466</ArticleId><ArticleId IdType="pubmed">35014610</ArticleId></ArticleIdList></Reference><Reference><Citation>Milicic Stanic B, Maddox S, Des Souza AMA, Wu X, Henhranfard D, Ji H, Speth RC, Sandberg K. Male bias in ACE2 basic science research: missed opportunity for discovery in the time of COVID-19. Am J Physiol Regul Integr Comp Physiol. 2021;320:R925&#x2013;R937. doi: 10.1152/ajpregu.00356.2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8203415</ArticleId><ArticleId IdType="pubmed">33848207</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong W, Mead H, Tian L, Park JG, Garcia JI, Jaramillo S, Barr T, Kollath DS, Coyne VK, Stone NE, et al. . The K18-Human ACE2 transgenic mouse model recapitulates non-severe and severe COVID-19 in response to an infectious dose of the SARS-CoV-2 virus. J Virol. 2022;96:e0096421. doi: 10.1128/JVI.00964-21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754221</ArticleId><ArticleId IdType="pubmed">34668775</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu CJ, Lin WC, Chou YC, Yang CM, Wu HL, Cheng YH, Liu PC, Chang JY, Chen HY, Sun JR. Dynamic changes of the blood chemistry in Syrian hamsters post-acute COVID-19. Microbiol Spectr. 2022;10:e0236221. doi: 10.1128/spectrum.02362-21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865472</ArticleId><ArticleId IdType="pubmed">35196799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Kim J, Jang JY, Noh H, Park J, Jeong H, Jeon D, Uhm C, Oh H, Cho K, et al. . Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits. Front Immunol. 2022;13:1055811. doi: 10.3389/fimmu.2022.1055811</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9706212</ArticleId><ArticleId IdType="pubmed">36457995</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari S, Goel G, Kumar A. Natural and genetically-modified animal models to investigate pulmonary and extrapulmonary manifestations of COVID-19. Int Rev Immunol. 2022;25:1&#x2013;20. doi: 10.1080/08830185.2022.2089666</Citation><ArticleIdList><ArticleId IdType="pubmed">35757923</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>